Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00208182 · ClinicalTrials.gov registry record · Phase 4
Risperidone in the Treatment of PTSD in Women Survivors of Domestic Abuse and Rape Trauma
A Phase 4 study, sponsored by Creighton University.
- Completed
- Registry status
- Phase 4
- Development phase
- 20
- Enrollment target
NCT00208182 is a Phase 4 study that has completed, run by Creighton University. The registered enrollment target is 20 participants.
The verdict
NCT00208182, a Phase 4 study, has completed, sponsored by Creighton University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 20 participants
- Enrollment target
Study Summary
This medical study is an assessment of clinical response in women with Posttraumatic Stress Disorder (PTSD) due to domestic violence or rape trauma when treated with risperidone. Response to risperidone or placebo (inactive drug) is measured by Clinician Administered PTSD Scale (CAPS) and Treatment Outcomes PTSD Scale (TOP-8). Second, the effect of risperidone on depressive and anxiety symptoms will be assessed using the Hamilton Rating Scale for Anxiety, Hamilton Rating Scale for Depression and the Clinical Global Impression.
Interventions
- DRUG Risperidone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2001-07 |
| Est. Completion | 2004-08 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00208182
The ClinicalTrials.gov registry entry for NCT00208182 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Creighton University, which has 98 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Risperidone is the first listed.
NCT00208182 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00208182 about?
NCT00208182 is a clinical study titled "Risperidone in the Treatment of PTSD in Women Survivors of Domestic Abuse and Rape Trauma". This medical study is an assessment of clinical response in women with Posttraumatic Stress Disorder (PTSD) due to domestic violence or rape trauma when treated with risperidone. Response to risperidone or placebo (inactive drug) is measured by Clinician Administered PTSD Scale (CAPS) and Treatment ...
What is the current status of trial NCT00208182?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 20 participants. The study started on 2001-07. Estimated completion is 2004-08.
What interventions are being tested in trial NCT00208182?
The interventions under investigation include: Risperidone (DRUG).
Who is sponsoring clinical trial NCT00208182?
This trial is sponsored by Creighton University, which has 98 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.